Kristina Kriksciukaite

Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

Kerry A. Whalen, Brian H. White, James M. Quinn et al. · Molecular Cancer Therapeutics · 2019 · 66 citations · Full text

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo

Brian H. White, Kerry A. Whalen, Kristina Kriksciukaite et al. · Journal of Medicinal Chemistry · 2019 · 50 citations · Full text

Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone

Reginald L. Dean, Mark S. Todtenkopf, Daniel R. Deaver et al. · Pharmacology Biochemistry and Behavior · 2008 · 30 citations

Extended-release Naltrexone, Health Sciences, Pain Medicine +12

Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results.

Gerald S. Falchook, Johanna C. Bendell, Susanna V. Ulahannan et al. · Journal of Clinical Oncology · 2020 · 26 citations

Pathology, Pharmacotherapy, Expansion Cohort Results +16

First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.

Melissa L. Johnson, Tim Meyer, Daniel M. Halperin et al. · Journal of Clinical Oncology · 2018 · 22 citations

Cancer Management, Immunology, Pathology +22